Abstract:Therapeutic Advances in Drug Safety, Volume 14, Issue , January-December 2023. Aims:To investigate the safety of oral iron therapy in pregnant women with iron-deficiency anemia (IDA) in the real world.Methods:A retrospective analysis was performed on 1792 pregnant patients with IDA who received oral iron supplements from 12 hospitals in Shandong Province from 1 April to 31 June 2021; follow-up and adverse reactions were recorded. They were divided into six groups according to the treatment drugs.Results:The overall adverse reaction rate was 15.4%, and the main adverse reaction site was the digestive system. The incidence of all kinds of oral iron adverse reactions from high to low in order: compound ferrous sulfate and folic acid tablets (21.88%); iron proteinsuccinylate oral solution (20.90%); ferrous succinate tablets (19.76%); ferrous succinate sustained-release tablets (18.00%); iron polysaccharide complex capsule (12.06%); and iron dextran oral solution (6.94%). It was found that there was a significant difference in the incidence of adverse reactions among the six drugs (p < 0.05). Pairwise comparison showed that the incidence of adverse reactions was higher in the iron proteinsuccinylate oral solution than that in the iron polysaccharide complex capsule (p 0.05), but there was a significant difference in the incidence of adverse reactions in different gestational ages (p < 0.05). In Adverse Drug Reaction (ADR) patients, the adverse reaction result of most patients is recovery or improvement, and there was no serious adverse reaction outcome such as sequela and death.Conclusion:All the adverse reactions of oral iron were mainly gastrointestinal adverse reactions, and no heavy adverse reactions were found. Iron proteinsuccinylate oral solution has a higher incidence of adverse reactions than iron polysaccharide complex capsule. The results showed that oral iron was safer for anemia patients during pregnancy.Plain language summarySafety of oral iron in the treatment of iron-deficiency anemia during pregnancyIntroduction: The safety of different oral iron agents varies. At present, the safety evaluation of iron supplements in the treatment of anemia during pregnancy is mainly focused on intravenous iron supplements, and there is no comprehensive study on the safety of commonly used oral iron supplements. This study compared the safety of six commonly used oral iron supplements in the treatment of iron-deficiency anemia during pregnancy, aiming to provide a reference for clinical medication.Methods: We conducted a study involving 1792 patients in 12 hospitals in Shandong Province from 1 April to 31 June 2021.Results: Among the six groups, 276 ADR patients reported 302 adverse reactions. There were significant differences in the rates of adverse reactions among the six oral iron agents, and the incidence of adverse reactions in the iron proteinsuccinylate oral solution was significantly higher than that of iron polysaccharide complex capsules. The main incidence of adverse reactions was constipation (6.96%), and most of the outcomes were cured or improved.Conclusion: In this study, there were no heavy adverse reactions. The incidence of adverse reactions of iron proteinsuccinylate oral was higher than that of iron polysaccharide compound capsule. The results showed that oral iron had a good safety in patients with anemia during pregnancy.

Comparison of the efficacy and adverse effects of oral ferrous succinate tablets and intravenous iron sucrose: a retrospective study

A Randomized, Controlled, Open Label Non-Inferiority Trial of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Patients with Iron Deficiency Anemia in China.

Intravenous iron sucrose in maintenance hemodialysis patients: a prospective randomized controlled multi-center clinical trial

The Effectiveness and Side Effects of Ferrous Lactate Tablets for Patients with Iron Deficiency Anemia

Comparitive Study on Three Iron Preparations for Treatment of Iron Deficiency Anemia: A Randomized-Controlled Trial

Oral versus intravenous iron therapy in iron deficiency anemia: An observational study

Comparison of Therapeutic Efficiency Between Saccharum Iron and Ferrum Dextran Iron: a Multicenter Clinical Trial

Intravenous iron sucrose therapy in anemic hemodialysis patients: a prospective randonmized controlled multicentric clinical trial

Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study

COMPARISON OF ORAL IRON SUPPLEMENTS (FERROUS SULPHATE) V/S PARENTRAL IRON SUPPLEMENT (IRON SUCROSE) IN ANTENATAL PATIENTS AT DHIRAJ GENERAL HOSPITAL, VADODARA

COMPARATIVE BIOTECHNOLOGICAL EVALUATION OF IRON SUPPLEMENTATION MODALITIES FOR PREGNANCY-RELATED ANEMIA: INTRAVENOUS IRON SUCROSE VS. ORAL FERROUS FUMARATE AND SULFATE

Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience

Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-dialysis Chronic Kidney Disease Patients: A Non-inferiority Study

The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia A Randomized Clinical Trial

Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD

Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator

A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial

Biodistribution and predictive hepatic gene expression of intravenous iron sucrose

The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia

Tolerability of different oral iron supplements: a systematic review

A comprehensive study of intravenous iron-carbohydrate nanomedicines: From synthesis methodology to physicochemical and pharmaceutical characterization